LeMaitre Vascular
LMAT
145 hedge funds and large institutions have $541M invested in LeMaitre Vascular in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 59 increasing their positions, 42 reducing their positions, and 19 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 42
20% more capital invested
Capital invested by funds: $451M → $541M (+$89.6M)
0.5% more ownership
Funds ownership: 79.25% → 79.76% (+0.5%)
3% less funds holding
Funds holding: 150 → 145 (-5)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$7.83M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$3.69M |
| 3 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$1.88M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.57M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.33M |
LMAT Hedge Fund Activity: Q3 2019 in Review
145 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q3 2019, worth a combined $541M — up 20% from $451M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LMAT and 14 opened new positions — a net loss of 5 holders — while 42 trimmed existing stakes and 59 added.
The largest buyer was Russell Investments Group, adding an estimated $5.53M. The largest seller was Millennium Management, exiting entirely with an estimated $7.83M sold.
- 145 institutional investors held LeMaitre Vascular (LMAT) as of Q3 2019, down from 150 in Q2 2019.
- Funds reported $541M of LeMaitre Vascular stock for Q3 2019, up 20% quarter-over-quarter.
- 14 funds opened new LeMaitre Vascular positions in Q3 2019 and 19 closed out, a net change of -5 holders.
- The largest LeMaitre Vascular buyer in Q3 2019 was Russell Investments Group, an estimated $5.53M added.
- The largest LeMaitre Vascular seller in Q3 2019 was Millennium Management, an estimated $7.83M sold.
Based on aggregated 13F filings for Q3 2019.